Update on the Acute Effects of Glucose, Insulin, and Incretins on Bone Turnover In Vivo

Overview

Journal Curr Osteoporos Rep

Publisher Current Science

Specialties Endocrinology
Orthopedics

Date 2020 Jun 7

PMID 32504189

Citations 7

Authors

Vanessa D Sherk

Irene Schauer

Viral N Shah

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: To provide an update on the acute effects of glucose, insulin, and incretins on markers of bone turnover in those with and without diabetes.

Recent Findings: Bone resorption is suppressed acutely in response to glucose and insulin challenges in both healthy subjects and patients with diabetes. The suppression is stronger with oral glucose compared with intravenous delivery. Stronger responses with oral glucose may be related to incretin effects on insulin secretion or from a direct effect on bone turnover. Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-2 (GLP-2) infusion acutely suppresses bone resorption without much effect on bone formation. The bone turnover response to a metabolic challenge may be attenuated in type 2 diabetes, but this is an understudied area. A knowledge gap exists regarding bone turnover responses to a metabolic challenge in type 1 diabetes. The gut-pancreas-bone link is potentially an endocrine axis. This linkage is disrupted in diabetes, but the mechanism and progression of this disruption are not understood.

Citing Articles

Training with reduced carbohydrate availability affects markers of bone resorption and formation in male academy soccer players from the English Premier League.

Stables R, Anderson L, Sale C, Hannon M, Dunn R, Tang J Eur J Appl Physiol. 2024; 124(12):3767-3780.

PMID: 39154306 PMC: 11569010. DOI: 10.1007/s00421-024-05574-4.

Physiological Appetite Regulation and Bariatric Surgery.

Ramasamy I J Clin Med. 2024; 13(5).

PMID: 38546831 PMC: 10932430. DOI: 10.3390/jcm13051347.

Effects of Exogenous GIP and GLP-2 on Bone Turnover in Individuals With Type 2 Diabetes.

Skov-Jeppesen K, Christiansen C, Hansen L, Windelov J, Hedback N, Gasbjerg L J Clin Endocrinol Metab. 2024; 109(7):1773-1780.

PMID: 38217866 PMC: 11180509. DOI: 10.1210/clinem/dgae022.

Bone Structure and Turnover in Postmenopausal Women With Long-Standing Type 1 Diabetes.

Shah V, Qui S, Stoneback J, Qamar L, Ferguson V, Kohrt W JBMR Plus. 2023; 7(11):e10831.

PMID: 38025041 PMC: 10652172. DOI: 10.1002/jbm4.10831.

Bone resorption and incretin hormones following glucose ingestion in healthy emerging adults.

Lei W, Rodrick E, Belcher S, Kelly A, Kindler J J Clin Transl Endocrinol. 2023; 31:100314.

PMID: 36845829 PMC: 9950953. DOI: 10.1016/j.jcte.2023.100314.

References

Skov-Jeppesen K, Svane M, Martinussen C, Gabe M, Gasbjerg L, Veedfald S . GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men. Bone. 2019; 125:178-185. DOI: 10.1016/j.bone.2019.05.014. View

Moayeri A, Mohamadpour M, Mousavi S, Shirzadpour E, Mohamadpour S, Amraei M . Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: a systematic review and meta-analysis. Ther Clin Risk Manag. 2017; 13:455-468. PMC: 5395277. DOI: 10.2147/TCRM.S131945. View

Christensen M, Lund A, Calanna S, Jorgensen N, Holst J, Vilsboll T . Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia. J Clin Endocrinol Metab. 2017; 103(1):288-294. DOI: 10.1210/jc.2017-01949. View

Starup-Linde J, Lykkeboe S, Gregersen S, Hauge E, Langdahl B, Handberg A . Differences in biochemical bone markers by diabetes type and the impact of glucose. Bone. 2015; 83:149-155. DOI: 10.1016/j.bone.2015.11.004. View

Tonks K, White C, Center J, Samocha-Bonet D, Greenfield J . Bone Turnover Is Suppressed in Insulin Resistance, Independent of Adiposity. J Clin Endocrinol Metab. 2017; 102(4):1112-1121. DOI: 10.1210/jc.2016-3282. View

Hothersall E, Livingstone S, Looker H, Ahmed S, Cleland S, Leese G . Contemporary risk of hip fracture in type 1 and type 2 diabetes: a national registry study from Scotland. J Bone Miner Res. 2013; 29(5):1054-60. PMC: 4255308. DOI: 10.1002/jbmr.2118. View

Riquelme-Gallego B, Garcia-Molina L, Cano-Ibanez N, Sanchez-Delgado G, Andujar-Vera F, Garcia-Fontana C . Circulating Undercarboxylated Osteocalcin as Estimator of Cardiovascular and Type 2 Diabetes Risk in Metabolic Syndrome Patients. Sci Rep. 2020; 10(1):1840. PMC: 7000396. DOI: 10.1038/s41598-020-58760-7. View

Nauck M, Meier J . Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018; 20 Suppl 1:5-21. DOI: 10.1111/dom.13129. View

Mabilleau G, Mieczkowska A, Irwin N, Simon Y, Audran M, Flatt P . Beneficial effects of a N-terminally modified GIP agonist on tissue-level bone material properties. Bone. 2014; 63:61-8. DOI: 10.1016/j.bone.2014.02.013. View

10.

Henriksen D, Alexandersen P, Byrjalsen I, Hartmann B, Bone H, Christiansen C . Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone. 2004; 34(1):140-7. DOI: 10.1016/j.bone.2003.09.009. View

11.

Iki M, Fujita Y, Kouda K, Yura A, Tachiki T, Tamaki J . Hyperglycemic status is associated with an elevated risk of osteoporotic fracture in community-dwelling elderly Japanese men: The Fujiwara-kyo osteoporosis risk in men (FORMEN) cohort study. Bone. 2019; 121:100-106. DOI: 10.1016/j.bone.2019.01.005. View

12.

Torekov S, Harslof T, Rejnmark L, Eiken P, Jensen J, Herman A . A functional amino acid substitution in the glucose-dependent insulinotropic polypeptide receptor (GIPR) gene is associated with lower bone mineral density and increased fracture risk. J Clin Endocrinol Metab. 2014; 99(4):E729-33. DOI: 10.1210/jc.2013-3766. View

13.

Starup-Linde J, Vestergaard P . Biochemical bone turnover markers in diabetes mellitus - A systematic review. Bone. 2015; 82:69-78. DOI: 10.1016/j.bone.2015.02.019. View

14.

Gottschalck I, Jeppesen P, Hartmann B, Holst J, Henriksen D . Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome. Scand J Gastroenterol. 2008; 43(11):1304-10. DOI: 10.1080/00365520802200028. View

15.

Hidayat K, Du X, Shi B . Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies. Osteoporos Int. 2019; 30(10):1923-1940. DOI: 10.1007/s00198-019-04968-x. View

16.

Westberg-Rasmussen S, Starup-Linde J, Hermansen K, Holst J, Hartmann B, Vestergaard P . Differential impact of glucose administered intravenously or orally on bone turnover markers in healthy male subjects. Bone. 2017; 97:261-266. DOI: 10.1016/j.bone.2017.01.027. View

17.

Bergmann N, Lund A, Gasbjerg L, Jorgensen N, Jessen L, Hartmann B . Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes. J Clin Endocrinol Metab. 2019; 104(7):2953-2960. DOI: 10.1210/jc.2019-00008. View

18.

Nissen A, Marstrand S, Skov-Jeppesen K, Bremholm L, Hornum M, Andersen U . A Pilot Study Showing Acute Inhibitory Effect of GLP-1 on the Bone Resorption Marker CTX in Humans. JBMR Plus. 2019; 3(10):e10209. PMC: 6820456. DOI: 10.1002/jbm4.10209. View

19.

Gottschalck I, Jeppesen P, Holst J, Henriksen D . Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract. Scand J Gastroenterol. 2008; 43(8):929-37. DOI: 10.1080/00365520801965381. View

20.

Chen S, Shepherd S, McMillan M, McNeilly J, Foster J, Wong S . Skeletal Fragility and Its Clinical Determinants in Children With Type 1 Diabetes. J Clin Endocrinol Metab. 2019; 104(8):3585-3594. DOI: 10.1210/jc.2019-00084. View